Adopting foreign price controls “prevents investors from being able to invest, and inventors from being able to invent.”
In a new video, Alex Karnal, a life science investor and partner at Deerfield Management, shares why investing in new cures and treatments is personal, and he explains how President Trump’s plan to import foreign price controls would have an “absolutely chilling” effect on investments in transformational, life-saving therapies.
“President Trump, we have got to lower drug prices at the pharmacy counter right now. In order to do that, we need four key groups to come together … and derive a holistic solution to treat the disease versus using foreign reference pricing as a scheme to focus on a single symptom.”
To learn more about the flaws of importing foreign price controls, visit bio.org/save-cures.
- The Challenges and Risks of Adopting Foreign Price Controls
- Oncologist Warns of IPI’s Potentially Dangerous Implications
- Despite Administration’s “Sky-High Rhetoric,” Importing Foreign Price Controls Will Harm Innovation and Patient Access
- Issue Brief: International Reference Pricing